Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Items 301–400 of 682
Vitzel, K. F., Bikopoulos, G. J., Hung, S., Pistor, K., Patterson, J. D., Curi, R., & Ceddia, R. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062190 · Cited by 27
“As previously mentioned, the hyperglycemic hepatic glycogenolytic and gluconeogenic effects of glucagon [39] likely offset the potentially glucose-lowering effect that AICAR exerted by increasing glycogen accumulation in skeletal muscles.”
Design principles of the paradoxical feedback between pancreatic alpha and beta cells
Garzilli, I., & Itzkovitz, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-29084-4 · Cited by 29
Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression
Nason, S. R., Kim, T., Antipenko, J. P., Finan, B., DiMarchi, R., Hunter, C. S., & Habegger, K. M. (2020) · Endocrinology · doi:10.1210/endocr/bqz013 · Cited by 26
β-Arrestins as Important Regulators of Glucose and Energy Homeostasis
Pydi, S. P., Barella, L. F., Zhu, L., Meister, J., Rossi, M., & Wess, J. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-060721-092948 · Cited by 25
Kjeldsen, S. A. S., Hansen, L. H., Esser, N., Mongovin, S., Winther‐Sørensen, M., Galsgaard, K. D., Hunt, J. E., Kissow, H., Ceutz, F. R., Terzic, D., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab084 · Cited by 26
Leptin therapy in type 2 diabetes
Cummings, B. P. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12048 · Cited by 23
“These findings suggest that glucagon is potentially an efficacious target for the treatment of diabetes [45], which is supported by the finding that the glucagon receptor knockout mouse is resistant to developing diabetes [46].”
BackgroundLiving without insulin: the role of leptin signaling in the hypothalamus
Fujikawa, T., & Coppari, R. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00108 · Cited by 24
“…nucleus; PVH, paraventricular hypothalamus; AgRP, Agouti-related peptide; RIP, rat insulin promoter; MC4R, melanocortin receptor 4; CRH, corticotrophin-releasing hormone; HPA-axis, hypothalamus-pituitaryadrenal (HPA)-axis. actions (Yu et al., 2008; Wang et al., 2010; Unger and Cherrington, 2012).”
BackgroundSREBP1c-PAX4 Axis Mediates Pancreatic β-Cell Compensatory Responses Upon Metabolic Stress
Lee, G., Jang, H., Kim, Y. Y., Choe, S. S., Kong, J., Hwang, I., Park, J., Im, S., & Kim, J. B. (2018) · Diabetes · doi:10.2337/db18-0556 · Cited by 32
“Dysregulation of two pancreatic hormones, characterized by insulin insufficiency and hyperglucagonemia, leads to hyperglycemia and contributes to increased diabetes incidence (37).”
BackgroundJames, H. A., Gonsalves, W. I., Manjunatha, S., Dasari, S., Lanza, I. R., Klaus, K. A., Vella, A. V., Andrews, J. C., & Nair, K. S. (2022) · Diabetes · doi:10.2337/db22-0079 · Cited by 23
α-cell electrophysiology and the regulation of glucagon secretion
Gao, R., Acreman, S., Ma, J., Abdulkader, F., Wendt, A., & Zhang, Q. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0295 · Cited by 29
“Overall, the current data support the provocative glucagonocentric hypothesis proposed by Unger et al. that glucagon excess, rather insulin deficiency, is the sine qua non of diabetes (Unger & Cherrington 2012).”
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Glucose Control of Glucagon Secretion: There Is More to It Than KATP Channels
Gylfe, E. (2013) · Diabetes · doi:10.2337/db13-0193 · Cited by 23
“Diabetes is generally attributed to insulin deficiency, but it has become increasingly evident that glucagon excess accounts for many diabetic manifestations (1).”
BackgroundGlucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure
Melenovský, V., Beneš, J., Franeková, J., Kovář, J., Borlaug, B. A., Segeťová, M., Tura, A., & Pelikánová, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005290 · Cited by 24
Al-Aama, J. Y., Mahdi, H. B. A., Salama, M. A., Bakur, K., Alhozali, A. M., Mosli, H. H., Bahijri, S., Bahieldin, A., Willmitzer, L., & Edris, S. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s215528 · Cited by 26
Singh, B., Khattab, F., Chae, H., Desmet, L., Herrera, P. L., & Gilon, P. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101268 · Cited by 27
Liu, L., Tian, X., Ma, Y., Duan, Y., Zhao, X., & Pan, G. (2018) · Angewandte Chemie · doi:10.1002/ange.201804802 · Cited by 23
Chowdhury, S., Wang, S., Patterson, B. W., Reeds, D. N., & Wice, B. M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.10.003 · Cited by 24
“Glucagon also plays a central role in regulating insulin secretion and blood glucose levels and the glucagon response is dysregulated in humans with T2DM [51].”
Kjeldsen, S. A. S., Richter, M. M., Jensen, N. J., Nilsson, M. S. D., Heinz, N., Nybing, J. D., Linden, F. H., Høgh‐Schmidt, E., Boesen, M., Andersen, T. L., et al. (2024) · Diabetes · doi:10.2337/db23-0858 · Cited by 24
Current and Emerging Treatment Options in Diabetes Care
Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_7 · Cited by 23
O'Harte, F. P. M., Ng, M., Lynch, A. M., Conlon, J. M., & Flatt, P. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12713 · Cited by 22
“An earlier study in our laboratory showed that [S2a] dogfish glucagon and related analogues can activate both the GLP-1 and glucagon receptors without appreciable effects at the GIP receptor.38 This is an important finding because co-agonist peptides afford 0 30 60 90 12 0 0102030 S al in e [S 2a ]d og fis h gl uc ag…”
BackgroundMethodInfluentialThe human α cell in health and disease
Pettway, Y. D., Saunders, D. C., & Briššová, M. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0298 · Cited by 24
Regulation of Hepatic Metabolism, Recent Advances, and Future Perspectives
Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1224-4 · Cited by 23
Đorđević, M., Stepper, P., Feuerstein-Akgoz, C., Gerhäuser, C., Paunović, V., Tolić, A., Rajić, J., Dinić, S., Uskoković, A. S., Grdović, N., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1134478 · Cited by 22
“Frontiers in Endocrinology 11 pancreatic hormones (insulin and glucagon), which is perturbed in diabetes (bihormonal hypothesis of diabetes) (46).”
BackgroundGlycoprotein 130 Receptor Signaling Mediates α-Cell Dysfunction in a Rodent Model of Type 2 Diabetes
Chow, S., Speck, M., Yoganathan, P., Nąckiewicz, D., Hansen, A. M. K., Ladefoged, M., Rabe, B., Rose‐John, S., Voshol, P. J., Lynn, F. C., et al. (2014) · Diabetes · doi:10.2337/db13-1121 · Cited by 21
“However, during type 2 diabetes, glucagon secretion is inappropriately elevated, contributing to hyperglycemia (5,6).”
BackgroundMeister, J., Wang, L., Pydi, S. P., & Wess, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15314 · Cited by 22
“4.1.3 | α- cell- specific GiD mice Pancreatic α- cells store and release glucagon which functions to maintain euglycemia and to counteract the actions of insulin on the liver and other tissues (Ahren, 2015; Quesada et al., 2008; Unger & Cherrington, 2012).”
BackgroundInfluentialCentral regulation of glucose metabolism in an insulin‐dependent and ‐independent manner
Fujikawa, T. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12941 · Cited by 22
Pedersen, C., Porsgaard, T., Thomsen, M., ROSENKILDE, M. M., & Roed, N. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194468 · Cited by 21
“Furthermore, several lines of evidence indicate that excess glucagon plays a pathophysiological role in the development of diabetes [35].”
Gap junction coupling and islet delta-cell function in health and disease
MIRANDA, C. A., Samad, M., Vergari, E., & Briant, L. J. B. (2021) · Peptides · doi:10.1016/j.peptides.2021.170704 · Cited by 23
Ueno, S., Seino, Y., Hidaka, S., Nakatani, M., Hitachi, K., Murao, N., Maeda, Y., Fujisawa, H., Shibata, M., Takayanagi, T., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14032 · Cited by 21
Riahi, Y., Kogot‐Levin, A., Kadosh, L., Agranovich, B., Malka, A., Assa, M., Piran, R., Avrahami, D., Gläser, B., Gottlieb, E., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05967-8 · Cited by 22
“It has even been hypothesised that diabetes is an alpha cell rather than a beta cell disease [1, 45].”
BackgroundNew strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy
Namba, M., Katsuno, T., Kusunoki, Y., Matsuo, T., Miuchi, M., & Miyagawa, J. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0709-0 · Cited by 22
A new paradigm for treating obesity and diabetes mellitus
Scheen, A. J., & Paquot, N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.3 · Cited by 24
Zhang, Y., Thai, K., Jin, T., Woo, M., & Gilbert, R. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-32351-z · Cited by 20
Beneficial metabolic role of β-arrestin-1 expressed by AgRP neurons
Pydi, S. P., Cui, Z., He, Z., Barella, L. F., Pham, J., Cui, Y., Oberlin, D. J., EĞRİTAĞ, H. E., Urs, N. M., Gavrilova, O., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz1341 · Cited by 20
Absence of leptin triggers type 1 diabetes
Mittendorfer, B., & Klein, S. (2014) · Nature Medicine · doi:10.1038/nm.3629 · Cited by 20
Lang, S., Wei, R., Wei, T., Gu, L., Feng, J. B., Yan, H., Yang, J., & Hong, T. (2020) · Peptides · doi:10.1016/j.peptides.2020.170349 · Cited by 19
Ito, A., Horie, I., Miwa, M., Sako, A., Niri, T., Nakashima, Y., Shigeno, R., Haraguchi, A., Natsuda, S., Akazawa, S., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13486 · Cited by 20
“Unger et al.(4) proposed that a paradoxical increase in glucagon release is the driving factor underlying hyperglycemia in type 1 diabetes and type 2 diabetes patients.”
BackgroundMagkos, F., Reeds, D. N., & Mittendorfer, B. (2022) · Physiological Reviews · doi:10.1152/physrev.00015.2022 · Cited by 21
Something old, something new and something very old: drugs for treating type 2 diabetes
Kaiser, D., & Oetjen, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12624 · Cited by 24
“The relevance for targeting glucagon receptors or α-cells to interfere with the pathogenesis of diabetes has long been neglected (D’Alessio, 2011; Unger and Cherrington, 2012).”
BackgroundYu, R., Ren, S.-G., & Mirocha, J. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.06.006 · Cited by 20
Gastrointestinal Hormones and Gut Endocrine Tumors
Vella, A. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00038-1 · Cited by 24
Liu, J., Liu, S., Gurung, R. L., Chan, C., Ang, K., Tang, W. E., Subramaniam, T., Sum, C. F., & Lim, S. C. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00321 · Cited by 21
“In consideration that a greater glucagon level might stimulate ketone body production [15, 24], we next examined the association of fasting glucagonwithb-hydroxybutyrate, themain component of ketone bodies.”
BackgroundHorie, I., Haraguchi, A., Ito, A., Nozaki, A., Natsuda, S., Akazawa, S., Mori, Y., Ando, T., Higashijima, A., Hasegawa, Y., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13096 · Cited by 20
Riopel, M., Moon, J.-S., Bandyopadhyay, G. K., You, S.-H., Lam, K., Liu, X., Kisseleva, T., Brenner, D. A., & Lee, Y. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101039 · Cited by 20
“Along with insulin resistance, hyperglucagonemia contributes to obesity-induced increased basal HGP [2].”
BackgroundInfluentialThe challenge of predicting blood glucose concentration changes in patients with type I diabetes
Borle, N. C., Ryan, E. A., & Greiner, R. (2021) · Health Informatics Journal · doi:10.1177/1460458220977584 · Cited by 22
The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
Guo, K., Tian, Q., Yang, L., & Zhou, Z. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s343514 · Cited by 20
“secretion of glucagon plays a key role in inducing hyperglycemia in patients with T1DM.(73) The early study(74)”
BackgroundMurai, N., Ohtaki, H., Watanabe, J., Xu, Z., Sasaki, S., Yagura, K., Shioda, S., Nagasaka, S., Honda, K., & Izumizaki, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186637 · Cited by 22
Sweatman, C. Z. W. H. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110037 · Cited by 22
Patterns of plasma glucagon dynamics do not match metabolic phenotypes in young women
Gar, C., Rottenkolber, M., Sacco, V., Moschko, S., Banning, F., Hesse, N., Popp, D., Hübener, C., Seissler, J., & Lechner, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02014 · Cited by 18
“(3, 4) first postulated that elevated glucagon is a sine qua non in the development of diabetes.”
BackgroundNot the second fiddle: α cell development, identity, and function in health and diabetes
Brooks, E. P., & Sussel, L. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0297 · Cited by 21
Intra-islet α-cell Gs signaling promotes glucagon release
Liu, L., EL, K. M., Dattaroy, D., Barella, L. F., Cui, Y., Gray, S. M., Guedikian, C., Chen, M., Weinstein, L. S., Knuth, E. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49537-x · Cited by 22
“This becomes hard to see with the expanded scale in Figure 1g.”
Postprandial Suppression of Glucagon Secretion: A Puzzlement
Geary, N. (2017) · Diabetes · doi:10.2337/dbi16-0075 · Cited by 19
“These and other data support the “bihormonal hypothesis of diabetes” that a relative lack of insulin secretion coupled to a relative surfeit of glucagon secretion leads to excessive hepatic glucose production and diabetes (5,9).”
BackgroundResultMTORC1 inhibition drives crinophagic degradation of glucagon
Rajak, S., Xie, S. Y., Tewari, A., Raza, S., Wu, Y., Bay, B., Yen, P. M., & Sinha, R. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101286 · Cited by 18
“This glucagon dysregulation contributes to hyperglycaemia through glucagon’s glycogenolytic and gluconeogenic effects on the liver [13].”
BackgroundA Novel Model and its Analysis on the Metabolic Regulations of Glucose, Insulin, and Glucagon
Cohen, R. B., & Li, J. (2021) · SIAM Journal on Applied Mathematics · doi:10.1137/21m1390876 · Cited by 20
The Brain–Liver Connection Between BDNF and Glucose Control
Jo, Y., & Chua, S. C. (2013) · Diabetes · doi:10.2337/db12-1824 · Cited by 20
“Diminishing glucagon action on the liver (1) and increasing leptin (2) are prime examples of promising peptide hormone treatments that could be useful in glucose regulation.”
BackgroundFu, B., Wang, X., Feng, X., Yu, X., & Tong, J. (2016) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2016.08.006 · Cited by 22
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
“…glucagon secretion in the postprandial period (due to the loss of paracrine inhibition by insulin secreted from the neighboring beta cells) [169,170], amylin deficiency represents an additional cause of poor postprandial glucose control, postprandial hyper-glucagonemia and increased…”
Bowman, C., Abramson, V. G., & Wellons, M. (2017) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709617725351 · Cited by 19
“Elevated glucagon and low relative endogenous insulin production increases lipolysis, releasing free fatty acids from adipose tissue, which are converted to ketone bodies.(15) Hypovolemia (via osmotic diuresis) also leads to increased cortisol/epinephrine/glucagon, further amplifying insulin resistance, ketogenesis, a…”
BackgroundGuzmán, C. B., Duvvuru, S., Akkari, P. A., Bhatnagar, P., Battioui, C., Foster, W. M., Zhang, X. M., Shankar, S. S., Deeg, M. A., Chalasani, N., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1171 · Cited by 17
“Dysregulated glucagon secretion with resultant hepatic glucose overproduction((1-3)) is an important pathophysiologic feature that contributes to chronic hyperglycemia in type 2 diabetes (T2D), and glucagon receptor antagonism has been shown to diminish hepatic glucose output and improve both fasting and postprandial…”
BackgroundJia, J., Kang, Q., Liu, S.-Z., Song, Y., Wong, F. S., Qiu, Y., & Li, M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15769 · Cited by 18
“Because the pancreatic alpha and beta cells arise from a common multipotent progenitor and the mass of alpha cells expands in diabetes, alpha cells are a desirable target for insulinproducing cell reprogramming (Thorel et al., 2010; Unger & Cherrington, 2012; Ye et al., 2015).”
BackgroundHepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia
Wang, Y., Spolitu, S., Zadroga, J. A., Sarecha, A. K., & Özcan, L. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111259 · Cited by 19
“A number of transcription factors and coactivators including, forkhead box O1 (FoxO1), cAMP response element-binding protein (CREB) and CREB-regulated transcription co-activator 2 (CRTC2) activate and stimulate the transcription of these gluconeogenic genes in T2D; however, little is known about the endogenous regulat…”
InfluentialKarambataki, M., Malousi, A., & Kouidou, S. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.09.005 · Cited by 18
“CGR, coding for a glucagon receptor, plays a key role in glucose etabolism and glucagon response [73] and homeostasis [74,75] nd its activation is involved in liver cell proliferation and regenration, as well as cancer prevention via -catenin signaling [76].”
BackgroundCoffee Ingestion Suppresses Hyperglycemia in Streptozotocin-Induced Diabetic Mice
Kobayashi, M., KURATA, T., HAMANA, Y., Hiramitsu, M., Inoue, T., Murai, A., & Horio, F. (2017) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.63.200 · Cited by 17
Silvestre, M. P., Goode, J. P., Vlaskovsky, P., McMahon, C., Tay, A., & Poppitt, S. D. (2017) · Obesity Reviews · doi:10.1111/obr.12631 · Cited by 17
“In line with this, a glucagon-centred view of diabetes has re-emerged.(11,12) Treatment with glucagon receptor antagonists performed over different periods of time has demonstrated robust glucose-lowering effects, with some glucagon receptor antagonists producing reductions in HbA1c levels comparable to, or greater th…”
BackgroundRole of glucagon in protein catabolism
Thiessen, S., Gunst, J., & den Berghe, G. V. (2018) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000509 · Cited by 18
Endocrine Function after Bariatric Surgery
Kim, K., & Sandoval, D. A. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160019 · Cited by 18
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Salomon‐Estebanez, M., Yau, D., Dunne, M. J., Worth, C., Birch, S., Walewski, J. L., & Banerjee, I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00441 · Cited by 17
Human Glucagon Expression Is under the Control of miR-320a
JO, S., Xu, G., Gu, J., Chen, J., & Shalev, A. (2020) · Endocrinology · doi:10.1210/endocr/bqaa238 · Cited by 20
Takatani, T., Shirakawa, J., Shibue, K., Gupta, M. K., Kim, H., Lu, S., Hu, J., White, M. F., Kennedy, R. T., & Kulkarni, R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100646 · Cited by 17
Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
Infante, M., Padilla, N., Alejandro, R., Caprio, M., Della‐Morte, D., Fabbri, A., & Ricordi, C. (2022) · Medicina · doi:10.3390/medicina58050571 · Cited by 19
Autocrine C‐peptide mechanism underlying INS1 beta cell adaptation to oxidative stress
Luppi, P., & Drain, P. F. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2528 · Cited by 16
“Like insulin, C-peptide is secreted dynamically in response to ever-changing glycaemia governed by meals and by liver glucose mobilization via the glucagon-insulin axis during fasting [2,3].”
BackgroundLi, X. C., & Zhuo, J. L. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0383-y · Cited by 17
Modelling of energy-driven switch for glucagon and insulin secretion
Grubelnik, V., Zmazek, J., Markovič, R., Gosak, M., & Marhl, M. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110213 · Cited by 15
Acreman, S., Ma, J., Denwood, G., Gao, R., Tarasov, A. I., Rorsman, P., & Zhang, Q. (2024) · iScience · doi:10.1016/j.isci.2024.109665 · Cited by 17
“4 It is well established that low ambient glucose levels stimulate and eu-, or hyperglycaemic concentrations inhibit glucagon secretion.”
Factors Affecting Insulin-Regulated Hepatic Gene Expression
Guan, H.-P., & Chen, G. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00006-5 · Cited by 18
Díaz‐Villaseñor, A., Granados, O., Palacios, B., Tovar‐Palacio, C., Torre-Villalvazo, I., Olivares-García, V., Torres, N., & Tovar, A. R. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.03.007 · Cited by 15
“Observations suggest that the action of glucagon is diabetogenic only under conditions of insulin resistance [60–62].”
BackgroundJiang, F., Li, K., Archer, M., Mehta, M., Jamieson, E. L., CHARLES, A. K., Dickinson, J. E., Matsumoto, M., & Morahan, G. (2017) · Stem Cells · doi:10.1002/stem.2567 · Cited by 17
Lysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3
Taddeo, E. P., Hargett, S. R., Lahiri, S., Nelson, M. E., Liao, J. A., Li, C., Slack‐Davis, J. K., Tomsig, J. L., Lynch, K. R., Yan, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00210-y · Cited by 15
Alsalim, W., Persson, M., & Åhrén, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13276 · Cited by 21
“expected to be of clinical importance for glucose homeostasis, as it is known that glucagon’s effect of increasing hepatic glucose production(4,11) is linearly related to its circulating levels.(17) Therefore, the”
BackgroundHosokawa, Y., Kozawa, J., Nishizawa, H., Kawamori, D., Maeda, N., Otsuki, M., Matsuoka, T., Iwahashi, H., & Shimomura, I. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e01715 · Cited by 15
“Glucagon promotes hepatic glucose output by enhancing glycogenolysis and gluconeogenesis, thereby contributes to a counteraction to hypoglycemia [1, 2].”
BackgroundKey Metabolic Functions of β-Arrestins: Studies with Novel Mouse Models
Pydi, S. P., Barella, L. F., Meister, J., & Wess, J. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.11.008 · Cited by 15
The glucose-mobilizing effect of glucagon at fasting is mediated by cyclic AMP
Albrechtsen, N. J. W. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00172.2021 · Cited by 18
Asadi, F., & Dhanvantari, S. (2021) · Islets · doi:10.1080/19382014.2021.2011550 · Cited by 17
“This paradoxical glucagon hypersecretion from α-cells then exacerbates hyperglycemia (Honzawa et al., 2019; Salehi et al., 2006; Unger and Cherrington, 2012).”
BackgroundAmino acids and the changing face of the α-cell
Hamilton, A., Eliasson, L., & Knudsen, J. G. (2023) · Peptides · doi:10.1016/j.peptides.2023.171039 · Cited by 17
“In diabetes, glucagon secretion becomes dysregulated with inappropriately high glucagon levels at high glucose, which compound the effects of insufficient insulin action driving diabetes pathogenesis [4].”
BackgroundFilippello, A., Scamporrino, A., Mauro, S. D., Malaguarnera, R., Pino, A. D., Scicali, R., Purrello, F., & Piro, S. (2020) · Biomolecules · doi:10.3390/biom10101404 · Cited by 15
Viloria, K., Hewison, M., & Hodson, D. J. (2021) · The Journal of Physiology · doi:10.1113/jp280890 · Cited by 15
Lee, C. J., Schnieders, J. H., Rubakhin, S. S., Patel, A. V., Liu, C., Naji, A., & Sweedler, J. V. (2022) · Metabolites · doi:10.3390/metabo12090799 · Cited by 14
“Although the islet pathology in type 2 diabetes is typically focused on insulin and beta cells, increased glucagon secretion and alpha cell function can also contribute to hyperglycemia in type 2 diabetes [44,45].”
BackgroundSigns of Glucagon Resistance After a 2-Week Hypercaloric Diet Intervention
Suppli, M. P., Høgedal, A., Bagger, J. I., Chabanova, E., van Hall, G., Forman, J. L., Christensen, M., Albrechtsen, N. J. W., Holst, J. J., & Knop, F. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad666 · Cited by 14
Targeting SUR1/Abcc8-Type Neuroendocrine KATP Channels in Pancreatic Islet Cells
Nakamura, Y., & Bryan, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091525 · Cited by 15
“increasingly understood to be a bihormonal disease characterized by dysregulation of insulin secretion from pancreatic b-cells and glucagon secretion from a-cells [1,2].”
BackgroundImpaired glucagon secretion in patients with fulminant type 1 diabetes mellitus
Komada, H., Hirota, Y., Sakaguchi, K., Okuno, Y., Ogawa, W., & Seino, S. (2018) · Endocrine · doi:10.1007/s12020-018-1750-x · Cited by 14
Stathmin-2 Mediates Glucagon Secretion From Pancreatic α-Cells
Asadi, F., & Dhanvantari, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00029 · Cited by 18
Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control
Lee, S. H., Park, H. Y., Yun, J. H., & Kyoung, E. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1645041 · Cited by 15
Goldenberg, R., Verma, S., Perkins, B. A., Gilbert, J. D., & Zinman, B. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.08.001 · Cited by 13
Lu, B., Chen, J., Xu, G., Grayson, T. B., Gu, J., JO, S., & Shalev, A. (2022) · Endocrinology · doi:10.1210/endocr/bqac133 · Cited by 14
Frost, P. A., Chen, S., Mezzles, M. J., Voruganti, V. S., Nava‐González, E. J., Arriaga-Cázares, H. E., Freed, K. A., Comuzzie, A. G., DeFronzo, R. A., Kent, J. W., et al. (2015) · Journal of Medical Primatology · doi:10.1111/jmp.12182 · Cited by 16
Takagi, Y., Kinoshita, K., Ozaki, N., Seino, Y., Murata, Y., Oshida, Y., & Hayashi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138322 · Cited by 13
“Glucagonocentrism was proposed as a new framework to facilitate such results whereby a lack of insulin was proposed to lead to glucagon excess, in turn causing diabetes abnormalities [27].”
BackgroundGregersen, S., Bystrup, S., Overgaard, A., Jeppesen, P. B., Thorup, A. C. S., Jensen, E., & Hermansen, K. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.252 · Cited by 13
Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
Armour, S. L., Frueh, A., & Knudsen, J. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837664 · Cited by 13
“In addition to the changes in insulin action or release, secretion of the counter regulatory hormone glucagon from pancreatic alpha cells is also altered (Marliss et al., 1970; Unger & Cherrington, 2012).”
BackgroundBrief overview: glucagon history and physiology
Robertson, R. P. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0224 · Cited by 16
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.